143
Participants
Start Date
May 27, 2020
Primary Completion Date
December 10, 2020
Study Completion Date
December 24, 2020
DFV890
DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
Standard of Care (SoC)
SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Novartis Investigative Site, San Martín de Porres
Novartis Investigative Site, San Miguel
Novartis Investigative Site, Budapest
Novartis Investigative Site, Hvidovre
Novartis Investigative Site, George
Novartis Investigative Site, Mexico City
Novartis Investigative Site, Madrid
Novartis Investigative Site, Hanover
Novartis Investigative Site, Monterrey
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Würzburg
Novartis Investigative Site, New Delhi
Novartis Investigative Site, New Delhi
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Ryazan
Novartis Investigative Site, Chelyabinsk
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Coimbatore
Novartis Investigative Site, Barnaul
Novartis Investigative Site, Krasnoyarsk
Novartis Investigative Site, Kolkata
Novartis Investigative Site, CABA
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Harderwijk
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY